中西医结合治疗非小细胞肺癌的研究概况
The Research Summary of Treating Nonsmall-Cell Lung Cancer with Traditional Chinese and Western Medicine
DOI: 10.12677/TCM.2017.61005, PDF, HTML, XML, 下载: 1,567  浏览: 3,788  科研立项经费支持
作者: 白浩然:上海中医药大学附属龙华临床医学院,上海;李和根:上海中医药大学附属龙华医院肿瘤科,上海
关键词: 非小细胞肺癌中医药综述Non-Small-Cell Lung Cancer Traditional Chinese Medicine Review
摘要: 肺癌是目前常见的恶性肿瘤之一,而且是当前威胁人们健康及生活质量,甚至生命的主要杀手,其发病率和死亡率在全球恶性肿瘤中占据首位。其中非小细胞肺癌(NSCLC)是肺癌中最为常见的,作为肺癌中的一大类别,在肺癌中占80%左右。手术治疗非小细胞肺癌具有疗效确切的特点,但许多晚期患者,无法接受手术治疗,且对放化疗等耐受性差。中医药治疗作为肿瘤治疗的一种方法,在长期的治疗实践中积累了丰富的经验,并与现代医学结合,得到了肿瘤学术界的认可。现将中西医结合治疗非小细胞肺癌的研究进展作一综述。
Abstract: As one of the most common malignant tumors, lung cancer is not only a health risk but the leading killer of human. Lung cancer is still among the most frequently occurring malignancies and is the leading cause of death in the world. Non-small-cell lung cancer (NSCLC) is the most common lung cancer and accounts for about 80% of all. Surgery remains the choice of treatment if patients are diagnosed at an early stage. However, for many patients in advanced stages who cannot choose surgery and tolerate intensive chemotherapy poorly, traditional Chinese medicine, combined with western medicine, could be an effective treatment with rich experience gained through long-term practice. This article will review the research progress of the treatment of non-small cell lung cancer with traditional Chinese medicine and western medicine.
文章引用:白浩然, 李和根. 中西医结合治疗非小细胞肺癌的研究概况[J]. 中医学, 2017, 6(1): 24-28. https://doi.org/10.12677/TCM.2017.61005

参考文献

[1] Stinchcombe, T.E. and SocinskI, M.A. (2008) Considerations for Second-Line Therapy of Non-Small Cell Lung Cancer. Oncologist, 13, 28-36. https://doi.org/10.1634/theoncologist.13-S1-28
[2] Mountain, C.F. (2010) Revisions in the International System for Staging Lung. Cancer, 11, 1710-1717.
[3] Hanna, N., Shepherd, F.A., Fossella, F.V., et al. (2004) Randomized Phase Ⅲ Trial of Pemetrexed versus Docetaxel in Patients with Non-Small-Cell-Lung Cancer Previously Treated with Chemotherapy. Journal of Clinical Oncology, 22, 1589-1597. https://doi.org/10.1200/JCO.2004.08.163
[4] Maruyama, R., Sugio, K., Mitsudomi, T., et al. (1977) Relationship between Early Recurrence and Micrometastases in the Lymph Nodes of Patients with Stage I Non-Small-Cell Lung Cancer. The Journal of Thoracic and Cardiovascular Surgery, 114, 535-543. https://doi.org/10.1016/S0022-5223(97)70041-2
[5] 林洪生. 通过循证建立指引,践行指引带动规范[C]//中国中西医结合学会肿瘤专业委员会, 中国抗癌协会传统医学委员会, 世界中医药学会联合会肿瘤专业委员会. 规范治疗与科学评价——第五届国际中医, 中西医结合肿瘤学术交流大会暨第十四届全国中西医结合肿瘤学术大会论文集. 2014: 12.
[6] 葛莉萍, 李坚, 陈萍. 培美曲塞联合顺铂一线治疗晚期非小细胞肺癌的临床研究[J]. 牡丹江医学院学报, 2015, 36(6): 17-19.
[7] 孙建立, 刘嘉湘. 金复康口服液对裸鼠人肺腺癌细胞凋亡相关基因表达的影响[J]. 上海中医药杂志, 2007, 41(10): 69-71.
[8] 孙建立, 孙玺媛, 刘嘉湘. 金复康口服液对耐药人肺腺癌A549/DDP膜转运蛋白LRP MRPmRNA表达的影响[J].辽宁中医药大学学报, 2009, 11(7): 210-213.
[9] 刘嘉湘, 施志明, 李和根, 等. 益肺抗瘤饮治疗271例非小细胞肺癌研究[J]. 医学研究通讯, 2003, 32(3): 23-24.
[10] 米成泉. 扶正抑癌方联合化疗治疗非小细胞肺癌的近期疗效及其对免疫功能的影响[J]. 现代肿瘤医学, 2015, 23(24): 3606-3609.
[11] 王斌. 人参多糖对晚期非小细胞肺癌患者生活质量及生存期的影响研究[J]. 中国中医药指南, 2015, 14(2): 179- 180.
[12] Marks, L.B., Yu, X., Vujaskovic, Z., et al. (2003) Radiation-Induced Lung Injury. Seminars in Radiation Oncology, 13, 333-345. https://doi.org/10.1016/s1053-4296(03)00034-1
[13] 封巍, 祝淑钗, 翟福山, 等. 三维适形放疗非小细胞肺癌所致食管损伤相关因素分析[J]. 中华放射肿瘤学杂志, 2005, 14(2): 94-98.
[14] 蔡红兵, 代方国, 阂清芬, 等. 中医药配合放疗治疗非小细胞肺癌的临床研究[J]. 第一军医大学学报, 2002, 22(12): 1112-1115.
[15] 柴小殊, 吴万巧, 李柳宁, 等. 扶正抗癌方联合吉非替尼治疗PS含2分晚期NSCLC的疗效与安全性研究[J]. 现代中西医结合杂志, 2014, 23(3):229-231.
[16] 李家曌. 肺抑瘤合剂配合厄洛替尼治疗肺腺癌的临床研究[D]: [硕士学位论文]. 济南: 山东中医药大学, 2010: 7- 10.
[17] 孙燕. β-榄香烯逆转吉非替尼耐药的作用及机制研究[D]: [硕士学位论文]. 杭州: 浙江中医药大学, 2014: 7-9.
[18] 张恩欣. 中医肿瘤学与靶向治疗的关系[J]. 中医研究, 2010, 23(6): 2-4.
[19] 薛娜, 淋洪生. 晚期非小细胞肺癌的中医维持治疗[J]. 临床肿瘤学杂志, 2012, 17(1): 1-5.